Targeting senescent cells with repurposed FDA-approved drugs improves phenotypes of aging in mice.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Bcl-2 family inhibitors sensitize human cancer models to therapy
Cell Death & Disease Open Access 17 July 2023
-
The relationship between epigenetic age and the hallmarks of aging in human cells
Nature Aging Open Access 16 May 2022
-
Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer
Nature Communications Open Access 21 April 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
López-Otín, C. et al. Cell 153, 1194–1217 (2013).
Childs, B. G. et al. Nat. Rev. Drug Discov. 16, 718–735 (2017).
Hernandez-Segura, A., Nehme, J. & Demaria, M. Trends Cell Biol. 28, 436–453 (2018).
Muñoz-Espín, D. & Serrano, M. Nat. Rev. Mol. Cell Biol. 15, 482–496 (2014).
Taguchi, J. & Yamada, Y. Cell Stem Cell 20, 293–294 (2017).
Sapieha, P. & Mallette, F.A. Trends Cell Biol. https://doi.org/10.1016/j.tcb.2018.03.003 (2018).
Xu, M. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0092-9 (2018).
Baker, D. J. et al. Nature 530, 184–189 (2016).
Zhu, Y. et al. Aging Cell 14, 644–658 (2015).
Zhu, Y. et al. Aging Cell 15, 428–435 (2016).
Biran, A. et al. Aging Cell 16, 661–671 (2017).
Newman, J. C. et al. J. Gerontol. A Biol. Sci. Med. Sci. 71, 1424–1434 (2016).
Acknowledgements
M.S. was funded by the Institute for Research in Biomedicine (IRB–Barcelona), by the “la Caixa” Foundation, by grants from the Spanish Ministry of Economy (cofunded by the European Regional Development Fund) and by the European Research Council (from the European Union’s Horizon 2020 research and innovation programme). The IRB–Barcelona is recipient of a Severo Ochoa Award of Excellence from the Spanish Ministry of Economy. N.B. is the recipient of grants from the National Institutes of Health (P01AG021654), the Nathan Shock Center of Excellence for the Biology of Aging (P30AG038072) and the Glenn Center for the Biology of Human Aging (Paul Glenn Foundation for Medical Research). Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.S. is the founder and a shareholder of Senolytic Therapeutics, Inc. (United States) and Senolytic Therapeutics, S.L. (Spain). N.B. is the founder of CohBar Inc. and a medical advisor to Life Biosciences.
Rights and permissions
About this article
Cite this article
Serrano, M., Barzilai, N. Targeting senescence. Nat Med 24, 1092–1094 (2018). https://doi.org/10.1038/s41591-018-0141-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0141-4
This article is cited by
-
Bcl-2 family inhibitors sensitize human cancer models to therapy
Cell Death & Disease (2023)
-
Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer
Nature Communications (2022)
-
The relationship between epigenetic age and the hallmarks of aging in human cells
Nature Aging (2022)
-
When dormancy fuels tumour relapse
Communications Biology (2021)
-
Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention
Signal Transduction and Targeted Therapy (2021)
